Mumbai, May 12 -- Piramal Pharma announced that the USFDA has issued an Establishment Inspection Report (EIR) for the company's Turbhe facility with Voluntary Action Indicated. The General Good Manufacturing Practices inspection inspection of the said facility was conducted between 11 February to 17 February 2025.

Published by HT Digital Content Services with permission from Capital Market....